Castle Biosciences
Castle Biosciences Estimates 2022 Revenues in Line With Prior Projections
The company said it expects full-year revenues of at least $132 million to $137 million, with test volumes up significantly across the majority of its menu.
In Brief This Week: NIH, Thermo Fisher Scientific, Biocept, Castle Biosciences, Biodesix
News items for the week of Nov. 21, 2022.
The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories.
Local Coverage Determinations Roundup: Castle Bio, SkylineDx
Palmetto GBA released a final local coverage determination that covers tests from Castle Biosciences and SkylineDx.
The firm is hoping that growing real-world evidence for DecisionDx-Melanoma will support better clinical recognition as it continues to expand its menu.
May 9, 2022
Castle Biosciences Q1 Revenues Grow 18 Percent
Apr 5, 2022
Castle Biosciences to Acquire AltheaDx for $65M
Feb 28, 2022
Castle Biosciences Q4 Revenues Grow 45 Percent
Feb 1, 2022
360Dx Top 30 Plummets 17 Percent in January
Nov 8, 2021
Castle Biosciences Q3 Revenues Rise 54 Percent
Oct 27, 2021
Aug 9, 2021